(P09) Combined Use of Radiosurgery With Concurrent PD-1/PD-L1 Inhibition For Metastatic Brain Lesions of NSCLC

Lung cancer is the leading cause of cancer death worldwide. The FDA first approved targeted PD-1/PD-L1 therapy for the treatment of advanced NSCLC in early 2015, and immunotherapies (IT) are becoming common in the setting of metastatic NSCLC. Some have hypothesized synergistic local and distant effects between stereotactic radiotherapy and IT, however data supporting safety and efficacy of their concurrent use has yet to be reported in the setting of SRS for brain metastasis from NSCLC. We evaluated overall survival (OS), time to intracranial progression (ICP), and acute adverse events (AEs) within our institution retrospective experience of PD-1/PD-L1 inhibitors and stereotactic radio surgery (SRS) for metastatic brain lesions of NSCLC.